Sanofi Ventures

Activity in this selectionOct 4, 2026 · Biotech · Jul 7, 2026

By stage

Series C+3

Series B2

Biotech5

United States2

Australia1

Israel1

United Kingdom1

5 in this selection

Aug 18

Develops immunotherapies that selectively deplete cytotoxic T cells to treat autoimmune diseases

$66MSeries D

Role not disclosed

Aug 10

Develops programmable epigenetic medicines to treat genetic diseases like FSHD

$90MSeries C

Role not disclosed

Aug 4

AI-driven platform that simulates clinical trials to predict outcomes before patient enrollment

$45MSeries B

Role not disclosed

Jul 15

Develops lead-212 targeted alpha therapies to treat cancer

$315MSeries D

Role not disclosed

Jul 14

Developing transformative, best-in-class neuropsychiatric therapies

$65MSeries B

Role not disclosed